Core Viewpoint - The approval of Weishiping by the NMPA marks a significant advancement in the treatment of moderate to severe active ulcerative colitis (UC) in China, addressing unmet clinical needs in this area [1][2] Group 1: Product Approval and Market Impact - Weishiping has been approved for use in adult patients with moderate to severe active UC who have inadequate response to traditional therapies or biologics [1] - The approval fills a critical gap in the treatment landscape for moderate to severe UC, providing a new oral treatment option aimed at deep mucosal healing [1] - The company plans to accelerate the commercialization process of Weishiping and aims to include it in the national medical insurance directory to enhance accessibility and affordability for patients [1] Group 2: Company Strategy and Future Outlook - The approval signifies a breakthrough for the company in the field of autoimmune diseases and enriches its commercial product matrix [1] - The company has established an integrated operation system driven by scientific and commercial insights, which will facilitate the efficient market launch of Weishiping [1] - The company has received new drug approvals for Weishiping in multiple regions, including China, the US, and the EU, and is constructing a local production facility to support long-term accessibility [2] - The company aims to achieve revenue exceeding 10 billion yuan by 2028 and over 15 billion yuan by 2030 through its commercialized products and comprehensive commercialization capabilities [2]
云顶新耀：维适平获批上市 将加快推进其商业化进程